Teeft.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Teeft.i » - entrée « Sdai »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Scrotum syndrome < Sdai < Sdai index  Facettes :

List of bibliographic references indexed by Sdai

Number of relevant bibliographic references: 42.
[0-20] [0 - 20][0 - 42][20-40]
Ident.Authors (with country if any)Title
002864 (2013) Philip G. Conaghan [Royaume-Uni] ; Patrick Durez [Belgique] ; Rieke E. Alten [Allemagne] ; Gerd-Rüdiger Burmester [Allemagne] ; Paul P. Tak [Pays-Bas, Royaume-Uni] ; Lars Klareskog [Suède] ; Anca Irinel Catrina [Suède] ; Julie Dicarlo [États-Unis] ; Corine Gaillez [France] ; Manuela Le Bars [France] ; Xianhuang Zhou [États-Unis] ; Charles Peterfy [États-Unis]Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
002A00 (2013) K. Kume ; K. Amano ; S. Yamada ; T. Kanazawa ; H. Ohta ; K. Hatta [Japon]THU0211 Combination of Intra-Articular Steroid Injection and Etanercept More Effective Than Etanercept in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, X Ray Reader Blinded Study
002A01 (2013) K. Funahashi ; I. Kashiwagi ; S. Koizumi ; T. Matsubara [Japon]THU0210 Satisfaction of RA Patients Using Biologics Correlates with Changes in Disease Activity from the Start of Administration
002A02 (2013) J. S. Smolen [Autriche] ; A. Kavanaugh [États-Unis] ; D. Van Der Heijde [Pays-Bas] ; S. Florentinus [France] ; S. S. Rathmann [États-Unis] ; H. Kupper [Allemagne] ; E. C. Keystone [Canada]THU0209 Disease Activity and Structural Damage-Related Differences in Functional Disability in Early and Established Rheumatoid Arthritis
002A06 (2013) S.-H. Park [États-Unis] ; I. Castrej N [États-Unis] ; J.-Y. Choe ; S.-K. Kim ; H.-J. Lee ; T. Pincus [États-Unis]THU0166 Associations of Formal Education Level with Rheumatoid Arthritis (RA) Core Data Set Variables and Indices in Korean Patients
002A07 (2013) I. Castrej N [États-Unis] ; M. Dougados [France] ; B. Combe [France] ; F. Guillemin [France] ; B. Fautrel [France] ; T. Pincus [États-Unis]THU0165 Predictive Value of Different Remission Criteria for a Good Functional Status Outcome: Results from the Espoir Cohort
002A08 (2013) I. Guseva ; N. Demidova ; N. Soroka [Russie] ; E. Panasyuk ; E. Luchikhina ; E. Fedorenko ; E. Alexandrova ; A. Novikov ; D. Trofimov [Russie] ; D. Karateev ; E. NasonovTHU0164 Polymorphism of Cytotoxic T-Lymphocyte Antigen 4 +49A/G is Associated with Refractoriness to Non-Biological Dmards in Rheumatoid Arthritis Patients
002A11 (2013) H. H. Nordal ; H. B. Hammer ; M. K. Fagerhol [Norvège] ; A. K. Halse [Norvège] ; R. Jonsson ; J. G. Brun [Norvège]THU0158 The Inflammatory Marker S100A12 is Highly Associated with a Comprehensive 78-Joints Ultrasonographic Synovitis Score in Patients with Rheumatoid Arthritis Treated with Adalimumab
002A24 (2013) B. Möller [Suisse] ; A. Scherer [Suisse] ; P. M. Villiger [Suisse] ; A. Finckh [Suisse]THU0129 Anemia Adds Information to Predict Radiographic Progression of Erosions on All Levels Levels of Clinically Assessed Disease Activity
002A38 (2013) L. Alifrangis [Danemark] ; P. André [France] ; V. Pascal ; E. Bonnet [France] ; L. Radzikowski [Danemark] ; M. B. Petersen [Danemark] ; M. Bléry [France]THU0110 Affinity and potency of the anti-NKG2A MAB NNC141-0100: Implications for mabel and dosing in the first-in-man trial in rheumatoid arthritis
002A39 (2013) K. Kume ; K. Amano ; K. Hatta ; H. Ohta [Japon]THU0109 Treating to target ultrasound with clinical remission better effects than clinical remission in RRP
002A40 (2013) J. Ducreux [Belgique] ; A. Nzeusseu Toukap [Belgique] ; F. A. Houssiau [Belgique] ; P. Durez [Belgique] ; B. Lauwerys [Belgique]THU0108 Global molecular effects of tocilizumab therapy in synovial biopsies of early RA patients
002B89 (2013) H. Radner [Autriche] ; F. Alasti [Autriche] ; J. S. Smolen [Autriche] ; D. Aletaha [Autriche]SAT0091 Physical function continues to improve in sustained clinical remission of rheumatoid arthritis (RA)
002E07 (2013) J. S. Smolen [Autriche] ; J. Wollenhaupt [Allemagne] ; P. Durez [Belgique] ; J. Gomez-Reino [Espagne] ; W. Grassi [Italie] ; M. Le Bars [France] ; C. Gaillez [France] ; C. Poncet [France] ; R. Westhovens [Belgique]FRI0242 Time to achieve remission and sustained remission for mtx-naïve patients with early ra treated with abatacept plus mtx versus mtx alone in the agree trial
002E22 (2013) D. Furst [États-Unis] ; K. L. Winthrop [États-Unis] ; K. A. Alexander ; A. Vashishtha ; S. F. Francom ; K. G. Saag [États-Unis]FRI0223 Long-term targeted safety event rates in ra patients following initiation of rituximab: interim analysis from sunstone registry
002E23 (2013) D. A. Pappas [États-Unis] ; A. John [États-Unis] ; J. R. Curtis [États-Unis] ; J. Kremer [États-Unis] ; W. Reiss ; A. Shewade [États-Unis] ; G. J. Silverman [États-Unis] ; J. Greenberg [États-Unis]FRI0222 Prevalence of low immunoglobulin levels and associations with rheumatoid arthritis factors
002E24 (2013) C. I. Daien ; S. Gailhac ; T. Mura [France] ; B. Combe ; M. Hahne ; J. MorelFRI0221 Tocilizumab increases regulatory t cells and nk cells cytotoxicity in rheumatoid arthritis patients
002E25 (2013) C. Codreanu ; I. Ancuta ; R. Ionescu [Roumanie]FRI0220 Sustained clinical efficacy after multiple courses of rituximab in rheumatoid arthritis patients with inadequate response to tumour necrosis factor inhibitors: 2-year data from the repeat (repeated courses in routine clinical practice) study
002E26 (2013) B. Missler-Karger [Allemagne] ; M. Leu ; M. A. Raboisson ; B. Pilstrom [Suède]FRI0219 Disease severity, no steroid use and type ii diabetes predict response to anakinra (kineret®) in patients with rheumatoid arthritis
002E27 (2013) A. Ogata [Japon]FRI0218 Normalization of c-reactive protein within the first 8 weeks is a predictive factor for the effectiveness of subcutaneous tocilizumab monotherapy in japanese rheumatoid arthritis patients: results from the musashi study
002E28 (2013) A. Kaneko [Japon] ; D. Kida [Japon] ; H. Ishikawa [Japon]FRI0217 Extended drug interval trial to clarify the efficacy of tocilizumab after stable status in

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i -k "Sdai" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i  \
                -Sk "Sdai" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Teeft.i
   |clé=    Sdai
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021